Ventyx Biosciences shares are trading lower after the company announced efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target to support further development of VTX958 in psoriasis.
Portfolio Pulse from Benzinga Newsdesk
Ventyx Biosciences announced that the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target, which does not support further development of VTX958 in psoriasis. This has led to a decrease in the company's share price.
November 07, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ventyx Biosciences' shares are trading lower after the company announced disappointing results from the Phase 2 trial of VTX958 in plaque psoriasis.
The announcement of the unsuccessful Phase 2 trial of VTX958 in plaque psoriasis has led to a decrease in Ventyx Biosciences' share price. This is because the results do not support further development of the drug, which could have been a potential revenue source for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100